Padagis
As of the edition of 20 October 2026, Padagis runs 8 drugs, 8 of them marketed.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 2 company names in this family.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 8 |
| Total | 8 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Budesonide | Ends 2029 (exclusivity) | 5 |
| Estradiol | Ends 2032 (patent) | 6 |
| Clindamycin | none listed | 0 |
| Mupirocin | none listed | 0 |
| Amiloride | none listed | 0 |
| Clindamycin phosphate | none listed | 0 |
| Butoconazole | none listed | 0 |
| Desonide | none listed | 3 |
A route B row is one company at one target.